Tumor sequencing before and after neoadjuvant chemoradiotherapy in locally advanced rectal cancer: Genetic tumor characterization and clinical outcome
Most oncogenic driver mutations investigated persisted after neoadjuvant treatment. At the same time, we did not observe ascending TMB after treatment but decline. Thus, NCRT does not seem to induce a relevant number of new driver mutations or mutational burden. Genetic profiling implies the potential to support tumor-informed approaches and outcome estimation in future.
Authors
- Leon Schütz (ORCID: https://orcid.org/0000-0001-7907-4878)
- Olga Kelemen
- Irina Bonzheim (ORCID: https://orcid.org/0000-0002-7732-0788)
- Cihan Gani (ORCID: https://orcid.org/0000-0003-0242-9428)
- Michael Orth (ORCID: https://orcid.org/0000-0002-4608-7151)
- Olaf Rieß (ORCID: https://orcid.org/0000-0002-7011-1369)
- Maximilian Niyazi (ORCID: https://orcid.org/0000-0002-7711-9486)
- Stephan Ossowski (ORCID: https://orcid.org/0000-0002-7416-9568)
- Christopher Schroeder
- Kerstin Clasen
- Nadja Ballin
Institutions
- University Children's Hospital Tübingen (DE)
- University of Tübingen (DE)
Publication Details
- Journal
- Clinical and Translational Radiation Oncology
- Published
- 2024-11-22
- DOI
- https://doi.org/10.1016/j.ctro.2024.100894
- Primary Topic
- Colorectal Cancer Surgical Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00